Experiences with CPP-based self assembling peptide systems for topical delivery of botulinum toxin

Methods in Molecular Biology

Volumn 1324, Issue , 2015, Pages 397-415

  Lee, Jane ^a   Kennedy, Phil ^a   Waugh, Jacob M ^a  

^a NONE

Author keywords

Botulinum toxin; Hyperhidrosis; Ionic; Lateral canthal lines; TAT

Indexed keywords

BOTULINUM TOXIN A; CELL PENETRATING PEPTIDE; EXCIPIENT; ACETYLCHOLINE RELEASE INHIBITOR; BOTULINUM TOXIN; DRUG CARRIER;

ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECEPTOR BINDING; SKIN IRRITATION; SKIN SENSITIZATION; UNSPECIFIED SIDE EFFECT; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; INTRADERMAL DRUG ADMINISTRATION; MOLECULAR GENETICS; SKIN DISEASES;

ACETYLCHOLINE RELEASE INHIBITORS; ADMINISTRATION, CUTANEOUS; AMINO ACID SEQUENCE; ANIMALS; BOTULINUM TOXINS; CELL-PENETRATING PEPTIDES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; HYPERHIDROSIS; MOLECULAR SEQUENCE DATA; SKIN DISEASES;

EID: 84938075406     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2806-4_27     Document Type: Article

References (27)

1. Scott AB (1981) Botulinum toxin injection of eye muscles to correct strabismus. Trauma Am Opthalmol Soc 79:734-770
2. Hallett M (1999) One man’s poison-clinical applications of botulinum toxin. N Engl J Med 341:118-120
3. Spencer JM (2002) Botulinum toxin B. The new option in cosmetic injection. J Drugs Dermatol 1:17-22
4. Carruthers A, Carruthers J (2005) Botulinum toxin type A. J Am Acad Dermatol 53: 284-290
5. Carruthers J, Carruthers A (2007) The evolution of botulinum toxin type A for cosmetic applications. J Cosmet Laser Ther 9:186-192
6. Carruthers J, Carruthers A (1992) Treatment of glabellar frown lines with C. botulinum - A exotoxin. J Dermatol Surg Oncol 18:17-21
7. Carruthers J, Fagien S, Matarasso SL, BOTOX Consensus Group (2004) Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg 114:1S-22S
8. The American Society for Aesthetic Plastic Surgery, Cosmetic Surgery National Data Bank. 2006 statistics. www.surgery.org/download/2006stats.pdf. Accessed 30 March 2007.
9. Bushara KO, Park DM, Jones JC, Schutta HS (1996) Botulinum toxin-a possible new treatment for axillary hyperhidrosis. Clin Exp Dermatol 21:276-278
10. Schnider P, Binder M, Berger T, Auff E (1996) Botulinum A toxin injection in focal hyperhidrosis. Br J Dermatol 134:1160-1161
11. Naumann M, Hofmann U, Bergmann I, Hamm H, Tiyka KV, Reiners K (1998) Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 134:301-304
12. Heckmann M, Ceballos-Baumann AO, Plewig G (2001) Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 344:488-493
13. Naumann M, Lowe NJ (2001) Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ 323:596-599
14. Lowe NJ, Lask G, Yamauchi P, Moore D (2002) Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow’s feet. J Am Acad Dermatol 47:834-840
15. Lowe NJ, Ascher B, Heckmann M, Kumar C, Fraczek S, Eadie N, BOTOX Facial Aesthetics Study Team (2005) Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow’s feet. Dermatol Surg 31:257-262
16. Matarasso SL, Matarasso A (2001) Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast Reconstr Surg 108:208-214
17. Allergan, Inc. (2006) BOTOX cosmetic (botulinum toxin type A) prescribing information. Irvine, CA
18. Aoki KR, Guyer B (2001) Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 8:21-29
19. Grumelli C, Verderio C, Pozzi D, Rossetto O, Montecucco C, Matteoli M (2005) Internalization and mechanism of action for clostridial toxins in neurons. Neurotoxicology 26:761-767
20. Dutton JJ, Fowler AM (2007) Botulinum toxin in ophthalmology. Surv Ophthalmol 52:13-31
21. Ford KG, Souberbielle BE, Darling D, Farzaneh F (2001) Protein transduction: an alternative to genetic intervention? Gene Ther 8:1-4
22. Aoki KR (2001) A comparison of the safety margins of botulinum toxin serotypes A, B, and F in mice. Toxicon 39:1815-1820
23. Koone MD, Black HS (1986) A mode of action for butylated hydroxytoluene-mediated photoprotection. J Invest Dermatol 87:343-347
24. Black HS (2002) Pro-oxidant and anti-oxidant mechanism(s) of BHT and beta-carotene in photocarcinogenesis. Front Biosci 7:d1044-d1055
25. Guyton KZ, Bhan P, Kuppusamy P, Zweier JL, Trush MA, Kensler TW (1991) Free radicalderived quinone methide mediates skin tumor promotion by butylated hydroxytoluene hydroperoxide: expanded role for electrophiles in multistage carcinogenesis. Proc Natl Acad Sci 88:946-950
26. Muhammad F, Brooks JD, Riviere JE (2004) Comparative mixture effects of JP-8(100) additives on the dermal absorption and disposition of jet fuel hydrocarbons in different membrane model systems. Toxicol Lett 150:351-365
27. Glogau RG (2007) Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. Dermatol Surg 33:S76-S80